Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the role of lifestyle changes and medication like metformin in managing insulin resistance and cardiovascular risk in women with polycystic ovary syndrome but reports no new clinical results.

In this study, baricitinib treatment improved the differentiation of skin-derived precursors into adipocytes for diseases like Hutchinson-Gilford progeria syndrome, suggesting potential benefits when combined with lonafarnib.

This study found that a combination of cyproterone acetate and ethinyl estradiol over one year did not affect glucose tolerance but increased total cholesterol, HDL cholesterol, and triglycerides in patients with moderate hyperandrogenism.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This article discusses ongoing and planned clinical chemoprevention trials for various agents and combinations but reports no new results; it highlights promising new agents and the evolving focus on molecular pathways.

This review discusses the pathophysiological characteristics and treatment options for polycystic ovary syndrome, reporting no new clinical results; the authors emphasize combining non-pharmacological measures with pharmacological treatments for optimal patient management.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

This paper is a quiz on contraceptive knowledge and reports no new research findings.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

In this retrospective cohort study, researchers found that exposure to 5-alpha reductase inhibitors and spironolactone in female alopecia patients was not linked to an increased risk of developing malignant or benign gynecologic tumors when compared to minoxidil use.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study reported that anti-androgens combined with lifestyle modifications were more effective than metformin and lifestyle in reducing hirsutism and certain hormonal measures in women with PCOS, but they were not more effective than a placebo combined with lifestyle changes.

This review discusses strategies for managing dermatological symptoms of hyperandrogenism in PCOS by reducing androgen levels and actions, and reports no new clinical results.

This study found that bolandiol increased lean body mass and bone mineral density in castrate adult male rats, exhibiting tissue selectivity and acting through multiple receptor pathways with less potency compared to other androgens.

This article examines the PCPT study on whether daily finasteride can reduce prostate cancer incidence, describing its methodology and findings but reporting no new clinical results.

In this study, a very-low-calorie diet led to greater weight loss and improvements in hyperandrogenaemia and metabolic markers in obese women with polycystic ovary syndrome compared to a moderate energy deficit approach over eight weeks.

This article reviews how to identify and manage androgenic alopecia caused by hormonal contraceptives but reports no new clinical findings.

This study observed that 62% of premenopausal women with female pattern hair loss reported improvement when treated with oral finasteride and an oral contraceptive containing drospirenone and ethinyl estradiol.

This study found that treatment with oral contraceptives containing 35mg ethinylestradiol and 2mg cyproterone acetate significantly reduced serum AMH levels in women with clomiphene citrate-resistant polycystic ovary syndrome, unlike metformin.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.

This review outlines diagnostic and treatment approaches for hirsutism, highlighting spironolactone or cyproterone acetate with oral contraceptives as the most effective therapy, and reports no new empirical results.

This study found that in non-obese women with moderate body hair growth, DHEA-S and prolactin levels were higher, and SBP was lower compared to controls, which may inform treatment decisions.

This study observed a strong overall reduction in the use of CPA/EE in the Netherlands, despite similar proportions of users with acne or other hyperandrogenic conditions before and after the referral procedure.

In this study, pioglitazone treatment in insulin-resistant PCOS patients decreased relative 5alpha-reductase activity without significantly affecting cortisol levels or urinary cortisol excretion.

Among obese women potentially eligible for combined oral contraceptives, this study observed a higher frequency of non-alcoholic fatty liver disease in those with polycystic ovary syndrome.

This study reviewed various dermatological conditions associated with oral contraceptive use, highlighting increased pigmentation, decreased sebum production, and changes in hair growth, among other effects.